Forecast
The analysts' average price target is €75.64 (+114.28%). The median is €75.64 (+114.28%).
| Buy |
Â
18 |
| Hold |
Â
6 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Apellis reaches 52-week high after takeover announcement by Biogen
Apellis shares rose to $40.87, marking a 52-week high; market capitalization is around $5.2 billion. Biogen announced the takeover, offering $41 per share in cash plus conditional value rights that could raise the price by up to $4, making the initial equity value about $5.6 billion. Analysts adjusted their ratings after the announcement, while valuation metrics—such as a P/E ratio of 237 and an overbought RSI—point to possible overvaluation. Despite roughly $1 billion in revenue in the past twelve months, Apellis is still unlikely to be profitable; the transaction is expected to close in Q2 2026. » More on de.investing.com
Apellis receives $5.6 billion offer from Biogen — shares about 140% higher premarket
Biogen is offering $5.6 billion for Apellis, paying $41 per share plus potential milestone payments related to Syfovre. The bid includes a hefty premium of 86% to the volume-weighted 90-day average price and 35% to the 52-week high. After the deal, Apellis shares rise nearly 140% in premarket trading; Biogen is likely primarily targeting Syfovre and the pegcetacoplan program. » More on deraktionaer.de
Apellis reports growth outlook for 2026 at TD Cowen conference despite operational hurdles
Apellis described 2025 as a transition year and expects accelerated revenue growth in 2026, supported by the launches of SYFOVRE and EMPAVELI. SYFOVRE showed a stable market position but is being hampered by disruptions in co‑pay programs, while EMPAVELI is off to a stronger‑than‑expected start in C3G/IC‑MPGN. The company closed 2025 with $466 million in cash and expects to have over $500 million in Q1 2026; a $94 million convertible bond maturing in September is planned to be serviced. The pipeline includes gene‑editing programs, FcRn programs and combination studies with a goal of reaching profitability. » More on de.investing.com
Apellis appoints Mikael Dolsten to the board
Apellis has appointed Mikael Dolsten, former chief scientific officer and president of research, development and medical at Pfizer, to its board. Dolsten was involved in the approval of more than 36 drugs and vaccines and brings extensive experience from senior roles at several pharmaceutical companies as well as advisory and consultancy positions. Apellis, a biopharma company focused on complement research with two approved C3‑directed drugs, has a market capitalization of about $2.68 billion and trailing twelve‑month revenue of roughly $1 billion; the stock trades at $20.96 and is down about 16.6% year‑to‑date. » More on de.investing.com
Apellis reports 2025 revenue growth and focuses on SYFOVRE prefilled syringe and pipeline expansion
Apellis released Q4 and full-year 2025 results with quarterly revenue of $199.9 million and annual revenue of about $1.0 billion (including a one-time license payment). SYFOVRE remains the market leader in geographic atrophy but showed a revenue decline in the quarter despite an increased number of injections; a prefilled syringe is expected to be filed in H1 2026. EMPAVELI recorded strong launch dynamics with a marked revenue increase and broad payer coverage. Apellis is advancing several innovation projects (OCT‑F imaging, APL‑3007, APL‑9099) and expects to reach profitability with existing liquidity, but faces a convertible bond maturing in Sept. 2026. » More on de.investing.com
Financials
In the last quarter, Apellis Pharmaceuticals had revenue of €231.78M and net profit of €16.12M
| (EUR) | March 2026 | YoY |
|---|---|---|
| Revenue | 231.78M | - |
| Gross profit | 196.5M | - |
| Net profit | 16.12M | - |
| EBITDA | 25.71M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.79B |
Number of shares | 128.02M |
52-week high/low | €37.49 - €15.14 |
| Dividends | No |
Beta | -0.25 |
P/E ratio | 38.71 |
PEG ratio | 0.07 |
P/B ratio | 12.46 |
P/S ratio | 4.75 |
Company profile
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
| Name | Apellis Pharmaceuticals |
| CEO | Cedric Francois |
| Headquarters | Waltham,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 11/09/2017 |
| Employees | 705 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | APLS |
Frankfurt | 1JK.F |
DĂĽsseldorf | 1JK.DU |
MĂĽnchen | 1JK.MU |